Bristol-Myers Squibb names new oncology development head

Bristol-Myers Squibb has announced the appointment of Dr Fouad Namouni as its new oncology development head, succeeding Dr Michael Giordano.

Dr Namouni has been with the company since 1999 and most recently served as head of medical. Prior to that, he served as development lead for the important therapies Yervoy and Opdivo.

In his new role, he will be responsible for leading the execution of a comprehensive development strategy for the company's robust oncology pipeline, from early development stage through to commercialisation.

Francis Cuss, executive vice-president and chief scientific officer of Bristol-Myers Squibb, said: "Fouad has demonstrated highly successful strategic and visionary leadership in oncology and immuno-oncology drug development and medical affairs throughout his career at Bristol-Myers Squibb."

Dr Giordano, meanwhile, has retired from Bristol-Myers Squibb after working with the business for more than 17 years. Since joining the company, he has been credited with leading the development and delivery of more than a dozen medicines to patients.